Neurodegenerative brain models vs. cell replacement or restoration therapy: A review on promises and pitfalls

Author(s):  
Dhiraj Kumar ◽  
Imtaiyaz Hassan
Neurosurgery ◽  
2020 ◽  
Author(s):  
Ben Jiahe Gu ◽  
David K Kung ◽  
Han-Chiao Isaac Chen

Abstract Cell therapy has been widely recognized as a promising strategy to enhance recovery in stroke survivors. However, despite an abundance of encouraging preclinical data, successful clinical translation remains elusive. As the field continues to advance, it is important to reexamine prior clinical trials in the context of their intended mechanisms, as this can inform future preclinical and translational efforts. In the present work, we review the major clinical trials of cell therapy for stroke and highlight a mechanistic shift between the earliest studies, which aimed to replace dead and damaged neurons, and later ones that focused on exploiting the various neuromodulatory effects afforded by stem cells. We discuss why both mechanisms are worth pursuing and emphasize the means through which cell replacement can still be achieved.


Cells ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 568
Author(s):  
Glen Lester Sequiera ◽  
Abhay Srivastava ◽  
Keshav Narayan Alagarsamy ◽  
Cheryl Rockman-Greenberg ◽  
Sanjiv Dhingra

Kearns Sayre syndrome (KSS) is mitochondrial multisystem disorder with no proven effective treatment. The underlying cause for multisystem involvement is the energy deficit resulting from the load of mutant mitochondrial DNA (mtDNA), which manifests as loss of cells and tissue dysfunction. Therefore, functional organ or cellular replacement provides a promising avenue as a therapeutic option. Patient-specific induced pluripotent stem cells (iPSC) have become a handy tool to create personalized cell -based therapies. iPSC are capable of self-renewal, differentiation into all types of body cells including cardiomyocytes (CM) and neural progenitor cells (NPC). In KSS patients, mutations in mtDNA are largely found in the muscle tissue and are predominantly absent in the blood cells. Therefore, we conceptualized that peripheral blood mononuclear cells (PBMNC) from KSS patients can be reprogrammed to generate mutation free, patient specific iPSC lines that can be used as isogenic source of cell replacement therapies to treat affected organs. In the current study we generated iPSC lines from two female patients with clinical diagnosis of classic KSS. Our data demonstrate that iPSC from these KSS patients showed normal differentiation potential toward CM, NPC and fibroblasts without any mtDNA deletions over passages. Next, we also found that functional studies including ATP production, reactive oxygen species generation, lactate accumulation and mitochondrial membrane potential in iPSC, CM, NPC and fibroblasts of these KSS patients were not different from respective cells from healthy controls. PBMNCs from these KSS patients in the current study did not reproduce mtDNA mutations which were present in muscle biopsies. Furthermore, we demonstrate for the first time that this phenomenon provides opportunities to create isogenic mutation free iPSC with absent or very low level of expression of mtDNA deletion which can be banked for future cell replacement therapies in these patients as the disease progresses.


1977 ◽  
Vol 233 (3) ◽  
pp. E208
Author(s):  
J Stragand ◽  
R F Hagemann

Recent studies have shown that the rate of colonic cell renewal can be altered through fasting and refeeding, which produces a marked depression and transient stimulation, respectively. In the present study, the role of physical versus nutritional stimulation in the colonic fasting-refeeding response and the renewal of the functional colonic compartment were evaluated via a nondestructive colonic ligation procedure. The results reported herein suggest that physical stimulation by lumenal factors is in part required to initiate the colonic hyperplasia seen after refeeding. Blood-borne nutritional factors, in the absence of physical stimulation, cannot alone stimulate colonic cell production. Additional evidence is presented which suggests that this physical stimulation may be manifested through the lumenal distension produced by the newly ingested food materials. The results are discussed from the viewpoint of influencing the functional colonic compartment and physiological capacity.


2004 ◽  
Vol 56 (11) ◽  
pp. 1661-1673 ◽  
Author(s):  
Tejal A. Desai ◽  
Teri West ◽  
Michael Cohen ◽  
Tony Boiarski ◽  
Arfaan Rampersaud
Keyword(s):  

2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Xiaojie Wang ◽  
Jianqiang Hao ◽  
Daniel L. Metzger ◽  
Ziliang Ao ◽  
Mark Meloche ◽  
...  

Type 1 diabetes (T1D) is a chronic autoimmune disease and characterized by absolute insulin deficiency.β-cell replacement by islet cell transplantation has been established as a feasible treatment option for T1D. The two main obstacles after islet transplantation are alloreactive T-cell-mediated graft rejection and recurrence of autoimmune diabetes mellitus in recipients. T cells play a central role in determining the outcome of both autoimmune responses and allograft survival. B7-H4, a newly identified B7 homolog, plays a key role in maintaining T-cell homeostasis by reducing T-cell proliferation and cytokine production. The relationship between B7-H4 and allograft survival/autoimmunity has been investigated recently in both islet transplantation and the nonobese diabetic (NOD) mouse models. B7-H4 protects allograft survival and generates donor-specific tolerance. It also prevents the development of autoimmune diabetes. More importantly, B7-H4 plays an indispensable role in alloimmunity in the absence of the classic CD28/CTLA-4 : B7 pathway, suggesting a synergistic/additive effect with other agents such as CTLA-4 on inhibition of unwanted immune responses.


Sign in / Sign up

Export Citation Format

Share Document